In Japan, a recombinant human ANP, carperitide, has been employed for the management of acute HF since 1995; it has been reported that the outcomes in patients with acute HF are better, and the agent can decrease pulmonary congestion in patients with systolic blood pressure of ≥120 mmHg [146]. Here, NPPA is linked to hydrops fetalis.